Crinetics Pharmaceuticals Adopts Excess Deferral Plan

Details

announced the adoption of the Excess Deferral Plan, an unfunded, non-qualified deferred compensation plan for select management and highly compensated employees, including named executive officers, effective April 1, 2024. The Plan allows participants to defer a portion of their compensation and receive matching or discretionary contributions from the Company, with full vesting for elective deferrals and matching contributions. Discretionary contributions vest according to a schedule set forth in the Plan.

Items reported

About Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.